Search

Displaying results 6731 - 6740 of 7399 in total
  1. Drug

    Flizasertib

    go.drugbank.com/drugs/DB21613
    Investigational

    Flizasertib is under investigation in clinical trial NCT06602453 (A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse

  2. Drug

    Eperisone

    go.drugbank.com/drugs/DB08992
    Investigational

    It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.

  3. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  4. Drug

    Utidelone

    go.drugbank.com/drugs/DB17575
    Investigational

    Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.

  5. Drug

    RLYB212

    go.drugbank.com/drugs/DB17727
    Investigational

    It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.

  6. Drug

    Dipropyl-4-hydroxytryptamine

    go.drugbank.com/drugs/DB13990
    Experimental

    Dipropyl-4-hydroxytryptamine was first synthesized by Alexander Shulgin. This agent and its properties haven't been fully elucidated.

    Synonyms: 4-HO-DPT, 4-Hydroxy-N,N-dipropyltryptamine
  7. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

  8. Drug

    Ro 24-7429

    go.drugbank.com/drugs/DB16062
    Investigational

    Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).

  9. Drug

    Triazavirin

    go.drugbank.com/drugs/DB15622
    Investigational

    [L12087] Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.[A191625]

  10. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]